Axsome Therapeutics (AXSM) Expected to Announce Quarterly Earnings on Tuesday

Axsome Therapeutics (NASDAQ:AXSM) is projected to post its quarterly earnings results before the market opens on Tuesday, February 18th. Analysts expect Axsome Therapeutics to post earnings of ($0.97) per share and revenue of $118.42 million for the quarter. Investors that are interested in registering for the company’s conference call can do so using this link.

Axsome Therapeutics (NASDAQ:AXSM) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($1.34) earnings per share for the quarter, topping the consensus estimate of ($1.38) by $0.04. Axsome Therapeutics had a negative return on equity of 158.36% and a negative net margin of 91.87%. The business had revenue of $104.76 million during the quarter, compared to analysts’ expectations of $98.71 million. During the same quarter in the previous year, the firm earned ($1.32) EPS. On average, analysts expect Axsome Therapeutics to post $-5 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Axsome Therapeutics Stock Up 20.2 %

Shares of AXSM stock opened at $127.08 on Tuesday. Axsome Therapeutics has a 12 month low of $64.11 and a 12 month high of $132.25. The company has a quick ratio of 2.37, a current ratio of 2.44 and a debt-to-equity ratio of 1.97. The firm has a market cap of $6.16 billion, a PE ratio of -19.46 and a beta of 1.05. The stock has a 50 day moving average of $94.72 and a 200-day moving average of $91.78.

Analyst Ratings Changes

A number of research firms recently weighed in on AXSM. William Blair reissued an “outperform” rating on shares of Axsome Therapeutics in a research report on Friday, January 24th. Needham & Company LLC reissued a “buy” rating and issued a $133.00 price target on shares of Axsome Therapeutics in a report on Monday. Leerink Partners increased their price objective on shares of Axsome Therapeutics from $110.00 to $150.00 and gave the company an “outperform” rating in a research note on Monday. HC Wainwright lifted their target price on shares of Axsome Therapeutics from $180.00 to $190.00 and gave the company a “buy” rating in a research report on Friday, January 31st. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $121.00 price target on shares of Axsome Therapeutics in a research report on Thursday, December 12th. One investment analyst has rated the stock with a hold rating and fifteen have issued a buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $135.14.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.